The risk of sudden cardiac death (SCD) or serious cardiac arrhythmias in patients with heart failure is particularly high in the initial period after an acute cardiac event.1,2  Also the clinical condition of patients often changes during this time.3  Therefore the medication is optimally adjusted in accordance with guideline recommendations before a decision is made on the necessity of further long-term therapy, such as the implantation of an implantable cardioverter defibrillator (ICD).4   Left-ventricular ejection fraction (LVEF) is still the most reliable predictor of this risk. According to the guidelines of the European Society of Cardiology (ESC) and of the American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society (HRS), patients with an LVEF ≤ 35% after an acute cardiac event should be considered for a wearable cardioverter defibrillator (WCD; LifeVest® ZOLL CMS) during the three-month drug therapy optimization phase.4, 5, 6  This approach is su